X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used toward developing Myosana’s platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: John Ballantyne
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 25, 2023
Details:
Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).
Lead Product(s): Non-viral gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CureDuchenne Ventures
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
